Evidence Hub

Untargeted Cross-Matrix Metabolomics Reveals Tryptophan Metabolism Shift in Children with Autism

Cai Y, Wu R, Teng X, Sun H, Abdillahi AFH, Zhang W, Li Z, Fan J

2026

33 participants

Abstract

Abstract Background Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder whose pathophysiological mechanisms remain unclear. A growing body of evidence suggests that gut microbiota dysbiosis is closely associated with ASD, with the microbiota-gut-brain axis (MGBA) serving as a central interactive pathway. Metabolomics can identify disease-related biomarkers and elucidate dysregulated metabolic pathways; however, current studies are largely limited to cross-sectional observations of a single biological matrix, lacking systematic research on metabolic transfer chains from the “local intestinal microenvironment” to the “host systemic circulation.” Methods A total of 33 children with ASD and 27 typical developings were enrolled. Urine and feces samples were collected and analyzed using a dual-platform approach with UHPLC-Q-TOF MS and UHPLC-Orbitrap Exploris™ 480 MS for non-targeted metabolomics. Differentially expressed metabolites were screened using a triple criterion of VIP > 1, Fold Change > 2 or

How strong is the evidence?

Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 33 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free